Histone deacetylase 5 promotes the proliferation of glioma cells by upregulation of Notch 1

Molecular Medicine Reports

Volumn 10, Issue 4, 2014, Pages 2045-2050

  Liu, Quan ^a   Zheng, Jie Min ^a   Chen, Jia Kang ^a   Yan, Xian Lei ^a   Chen, Hong Mou ^a   Nong, Wei Xia ^a   Huang, He Qing ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Cell proliferation; Glioma; HDAC5; Notch 1

Indexed keywords

HISTONE DEACETYLASE 5; NOTCH1 RECEPTOR; SMALL INTERFERING RNA; HDAC5 PROTEIN, HUMAN; HISTONE DEACETYLASE; MESSENGER RNA;

ARTICLE; ASTROCYTE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENE SILENCING; GLIOMA CELL; GLIOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; MTT ASSAY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; CHEMISTRY; GENETICS; GLIOMA; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; GLIOMA; HISTONE DEACETYLASES; HUMANS; RECEPTOR, NOTCH1; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84929411962     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2395     Document Type: Article

References (22)

1. Medina Villaamil V, Alvarez García A, Aparicio Gallego G, et al: Tissue array analysis for the differentiation of gliosis from gliomas. Mol Med Rep 4: 451-457, 2011.
2. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018, 2002.
3. Wang Y, Zhou Z, Luo H, et al: Combination of tamoxifen and antisense human telomerase RNA inhibits glioma cell proliferation and anti-apoptosis via suppression of telomerase activity. Mol Med Rep 3: 935-940, 2010.
4. Lefranc F, Facchini V and Kiss R: Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 12: 1395-1403, 2007.
5. Witt O, Deubzer HE, Milde T and Oehme I: HDAC family: What are the cancer relevant targets? Cancer Lett 277: 8-21, 2009.
6. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S and van Kuilenburg AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370: 737-749, 2003. (Pubitemid 36399066)
7. Voelter-Mahlknecht S, Ho AD and Mahlknecht U: Chromosomal organization and localization of the novel class IV human histone deacetylase 11 gene. Int J Mol Med 16: 589-598, 2005.
8. Sen N, Kumari R, Singh MI and Das S: HDAC5, a key component in temporal regulation of p53-mediated transactivation in response to genotoxic stress. Mol Cell 52: 406-420, 2013.
9. Witt O, Deubzer HE, Milde T and Oehme I: HDAC family: What are the cancer relevant targets? Cancer Lett 277: 8-21, 2009.
10. Wiegmans AP, Alsop AE, Bots M, et al: Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. Cancer Res 71: 3603-3615, 2011.
11. Munster P, Marchion D, Bicaku E, et al: Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 15: 2488-2496, 2009.
12. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
13. Ronsch K, Jager M, Schopflin A, Danciu M, Lassmann S and Hecht A: Class I and III HDACs and loss of active chromatin features contribute to epigenetic silencing of CDX1 and EPHB tumor suppressor genes in colorectal cancer. Epigenetics 6: 610-622, 2011.
14. Khan O and La Thangue NB: HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90: 85-94, 2012.
15. Roy S, Shor AC, Bagui TK, Seto E and Pledger WJ: Histone deacetylase 5 represses the transcription of cyclin D3. J Cell Biochem 104: 2143-2154, 2008.
16. McKinsey TA, Zhang CL, Lu J and Olson EN: Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 408: 106-111, 2000.
17. Milde T, Oehme I, Korshunov A, et al: HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res 16: 3240-3252, 2010.
18. Chen J, Xia J, Yu YL, et al: HDAC5 promotes osteosarcoma progression by upregulation of Twist 1 expression. Tumour Biol 35: 1383-1387, 2013.
19. Rana NA and Haltiwanger RS: Fringe benefits: functional and structural impacts of O-glycosylation on the extracellular domain of Notch receptors. Curr Opin Struct Biol 21: 583-589, 2011.
20. Ayukawa T, Matsumoto K, Ishikawa HO, et al: Rescue of Notch signaling in cells incapable of GDP-L-fucose synthesis by gap junction transfer of GDP-L-fucose in Drosophila. Proc Natl Acad Sci USA 109: 15318-15323, 2012.
21. Hu B, Nandhu MS, Sim H, et al: Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling. Cancer Res 72: 3873-3885, 2012.
22. Berry N, Gursel DB and Boockvar JA: Notch inhibition via micro-RNA blocks glioma development. Neurosurgery 70: N20-N22, 2012.